|Bid||1.6300 x 4000|
|Ask||1.6700 x 29200|
|Day's range||1.5400 - 1.6800|
|52-week range||0.9900 - 1.7400|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||N/A|
|Earnings date||09 Mar 2022 - 14 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.00|
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
FOSTER CITY, Calif., June 30, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.